Literature DB >> 6865273

[Non-Hodgkins's lymphomas - current aspects of clinical diagnosis and therapy].

D Huhn.   

Abstract

Non-Hodgkin-Lymphomas (NHL), classified according to "Kiel" or Rappaport", may be subdivided into those with low or with high malignancy. Corresponding to clinical stage and to histological subtype, therapeutic recommendations are discussed. 1. Limited stage: An irradiation with curative intention seems possible. In cases with unfavourable histology relapses are frequent, and an additional or exclusive therapy with cytostatics appears to be of increasing importance. 2. Advanced stages and favourable histology: The value of an early and intensive use of cytostatics is questioned. 3. Advanced stages and unfavourable histology: Cure of the lymphoma seems feasible when intensive cytostatic regimes are applied.

Entities:  

Mesh:

Year:  1983        PMID: 6865273     DOI: 10.1007/bf02664330

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  47 in total

1.  [Radiotherapy of non-Hodgkin's lymphomas].

Authors:  K Musshoff
Journal:  Hamatol Bluttransfus       Date:  1976

2.  Lymphosarcoma. A comparison of extended to conservative chemotherapy.

Authors:  J H Kaufman; E Ezdinli; C W Aungst; L Stutzman
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

3.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

4.  Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.

Authors:  B Koziner; C Little; S Passe; H T Thaler; R Sklaroff; D J Straus; B J Lee; B D Clarkson
Journal:  Cancer       Date:  1982-04-15       Impact factor: 6.860

5.  Deferral of initial therapy for advanced indolent lymphomas.

Authors:  C S Portlock
Journal:  Cancer Treat Rep       Date:  1982-03

6.  Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin's): correlation with clinical factors for diagnosis, prognosis, classification and staging.

Authors:  R Bartl; B Frisch; R Burkhardt; G Kettner; G Mahl; A Fateh-Moghadam; M Sund
Journal:  Br J Haematol       Date:  1982-08       Impact factor: 6.998

7.  Primary lymphoma of the central nervous system.

Authors:  L Letendre; P M Banks; D F Reese; R H Miller; P W Scanlon; J M Kiely
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

8.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

Review 9.  Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

Authors:  J Ritz; S F Schlossman
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

10.  Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report.

Authors:  E Z Ezdinli; W G Costello; M N Silverstein; C Berard; R J Hartsock; J E Sokal
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.